Genotype-guided coumarin dosing: Where are we now and where do we need to go next?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 4, 2015, Pages 509-522

  Baranova, Ekaterina V ^a   Verhoef, Talitha I ^b   Asselbergs, Folkert W ^b,c,d   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Coumarins; CYP2C9; Dose; Genetic guided; Pharmacogenetics; Polymorphism; VKORC1; Warfarin

Indexed keywords

ACENOCOUMAROL; AMIODARONE; COUMARIN DERIVATIVE; CYTOCHROME P450 2C9; DABIGATRAN; PHENPROCOUMON; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; VKORC1 PROTEIN, HUMAN;

ALGORITHM; COST EFFECTIVENESS ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHARMACOGENOMICS; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; DOSE RESPONSE; ETHNIC GROUP; GENETICS; PHARMACOGENETICS;

ALGORITHMS; ANTICOAGULANTS; COUMARINS; CYTOCHROME P-450 CYP2C9; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; GENETIC VARIATION; GENOTYPE; HUMANS; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASES;

EID: 84924766686     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1004053     Document Type: Review

References (97)

1. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet 2014;15:349-70
2. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286(18):2270-9
3. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015;25(1):33-41
4. Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006;21(1):73-7
5. Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008;84(3):301-3
6. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365(21):2002-12
7. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121(1):23-34
8. Cavallari LH, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther 2014;96(1):22-4
9. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009;30(7):375-86
10. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5(3):e1000433
11. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112(4):1022-7
12. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000;28(11):1284-90
13. Ufer M, Svensson JO, Krausz KW, et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004;60(3):173-82
14. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin. Blood 2005;105(2):645-9
15. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427(6974):537-41
16. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5(6):389-92
17. Teichert M, Eijgelsheim M, Rivadeneira F, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009;18(19):3758-68
18. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013;382(9894):790-6
19. Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010;19(23):4735-44
20. Teichert M, Eijgelsheim M, Uitterlinden AG, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet Genomics 2011;21(1):26-34
21. Scott SA, Edelmann L, Kornreich R, et al Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008;82(2):495-500
22. Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008;112(4):1013-21
23. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352(22):2285-93
24. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115(18):3827-34
25. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14(13):1745-51
26. Niinuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2014;14(2):107-14
27. Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol 2012;73(3):340-7
28. Schalekamp T, De Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des 2010;16(2):187-203
29. McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009;75(6):1337-46
30. Cavallari LH, Perera M, Wadelius M, et al. Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 2012;22(2):152-8
31. Bress A, Patel SR, Perera MA, et al. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 2012;13(16):1925-35
32. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010;87(4):445-51
33. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 2011;31(12):1192-207
34. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008;83(2):312-21
35. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287(13):1690-8
36. Meckley LM, Wittkowsky AK, Rieder MJ, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-Treated patients. Thromb Haemost 2008;100(2):229-39
37. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-Treated cohort supports genetic forecasting. Blood 2009;113(4):784-92
38. Teichert M, Van Schaik RH, Hofman A, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 2009;85(4):379-86
39. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-Treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7(2):97-104
40. Gaikwad T, Ghosh K, Kulkarni B, et al. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. Eur J Pharmacol 2013;710(1-3):80-4
41. Tomek A, Matoska V, Kolarova T, et al. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology 2013;125(3):182-91
42. Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-Treated patients: a systematic review and meta-analysis. Int J Cardiol 2013;168(4):4234-43
43. Verhoef TI, Redekop WK, Buikema MM, et al. Long-Term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012;10(4):606-14
44. Verhoef TI, Redekop WK, Hegazy H, et al. Long-Term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012;10(12):2610-12
45. Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol 2014;77(4):626-41
46. Wei M, Ye F, Xie D, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 2012;107(6):1083-91
47. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 2011;12(1):15-25
48. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84(3):326-31
49. International Warfarin Pharmacogenetics Consortium. Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753-64
50. Finkelman BS, Gage BF, Johnson JA, et al. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011;57(5):612-18
51. Dean L. Warfarin therapy and the genotypes CYP2C9 and VKORC1. 8 March 2012 Updated 2013 March 18 In: Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US), Bethesda, MD; 2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK84174/[Last accessed 21 October 2014]
52. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90(4):625-9
53. Rathore SS, Agarwal SK, Pande S, et al. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One 2012;7(5):e37844
54. Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One 2012;7(7):e41360
55. Geisen C, Luxembourg B, Watzka M, et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol 2011;67(4):371-81
56. Pop TR, Vesa S, Trifa AP, et al. An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol 2013;69(11):1901-7
57. Van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009;10(10):1687-95
58. Van Schie RM, el Khedr N, Verhoef TI, et al. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics 2012;13(11):1239-45
59. Baranova EV, Asselbergs FW, De Boer A, et al The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?. Curr Mol Med 2014;14(7):841-8
60. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369(24):2283-93
61. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369(24):2294-303
62. Verhoef TI, Ragia G, De Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369(24):2304-12
63. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010;87(5):572-8
64. Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing-recalibrating expectations. N Engl J Med 2013;369(24):2273-5
65. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009;19(3):226-34
66. Wang M, Lang X, Cui S, et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 2012;9(6):472-9
67. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014;174(8):1330-8
68. Liao Z, Feng S, Ling P, et al. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. J Thromb Thrombolysis 2014. [Epub ahead of print]
69. Goulding R, Dawes D, Price M, et al. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. Br J Clin Pharmacol 2014. [Epub ahead of print]
70. Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014;12(9):1480-7
71. Tang Q, Zou H, Guo C, et al. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis. Int J Cardiol 2014;175(3):587-91
72. Do EJ, Lenzini P, Eby CS, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2012;12(5):417-24
73. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150(2):73-83
74. Leey JA, McCabe S, Koch JA, et al. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother 2009;7(4):197-203
75. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009;2(5):429-36
76. You JH, Tsui KK, Wong RS, et al. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotypeguided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009;86(5):540-7
77. Schalekamp T, Oosterhof M, Van Meegen E, et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004;76(5):409-17
78. Meckley LM, Gudgeon JM, Anderson JL, et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28(1):61-74
79. Verhoef TI, Redekop WK, Van Schie RM, et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 2012;13(12):1405-17
80. Shiroiwa T, Sung YK, Fukuda T, et al International survey on willingness-To-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010;19(4):422-37
81. Verhoef TI, Redekop WK, Darba J, et al. A systematic review of costeffectiveness analyses of pharmacogeneticguided dosing in treatment with coumarin derivatives. Pharmacogenomics 2010;11(7):989-1002
82. Verhoef TI, Redekop WK, Veenstra DL, et al. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacogenomics 2013;14(8):869-83
83. Verhoef TI, Redekop WK, De Boer A, et al. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. Pharmacogenomics 2013; In press
84. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333
85. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62
86. Pink J, Pirmohamed M, Lane S, et al. Cost-effectiveness of pharmacogeneticsguided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2014;95(2):199-207
87. You JH, Tsui KK, Wong RS, et al. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One 2012;7(6):e39640
88. You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a costeffectiveness analysis. Pharmacogenet Genomics 2014;24(1):6-14
89. Howard R, Leathart JB, French DJ, et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clin Chim Acta 2011;412(23-24):2063-9
90. Nutescu EA, Dager WE, Kalus JS, et al. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm 2013;70(21):1914-29
91. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J 2014;14(3):223-8
92. Maitland-van Der Zee AH, Daly AK, Kamali F, et al. Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther 2014;96(1):15-17
93. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotypeguided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116(22):2563-70
94. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008;83(3):460-70
95. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011;13(6):509-18
96. Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost 2012;108(3):561-9
97. Jonas DE, Evans JP, McLeod HL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics 2013;14(13):1593-603